<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="148187">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02152787</url>
  </required_header>
  <id_info>
    <org_study_id>3-2014-0028</org_study_id>
    <nct_id>NCT02152787</nct_id>
  </id_info>
  <brief_title>Comparison of Propofol 1mg/kg and Propofol 0.5mg/kg for Prevention of Emergence Agitation in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia</brief_title>
  <official_title>Comparison of Propofol 1mg/kg and Propofol 0.5mg/kg for Prevention of Emergence Agitation in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The occurrence of emergence agitation (EA) in pediatric patients who have received
      sevoflurane anesthesia is a common postoperative problem. Among various strategies for
      reducing the incidence and severity of EA, the use of pharmacological agents at the end of
      anesthesia is thought to be the most convenient and easily applicable method in clinical
      situation. The one of typical agents that can be administered in this way is propofol.
      Previous studies demonstrated that the use of propofol 1mg/kg at the end of anesthesia could
      reduce the incidence of EA with low incidence of postoperative nausea and vomiting. However,
      it was also demonstrated that the use of propofol 1mg/kg at the end of anesthesia could
      delay the emergence time. The purpose of this study is to compare the preventive effect on
      EA and the emergence time between propofol 1mg/kg and propofol 0.5mg/kg administered at the
      end of sevoflurane anesthesia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The incidence of the emergence agitation</measure>
    <time_frame>from extubation up to 1 hour</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>the emergence time</measure>
    <time_frame>within the first 1hour after end of strabismus surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>The emergence time was defined as the time from discontinuation of sevoflurane to extubation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Strabismus</condition>
  <arm_group>
    <arm_group_label>1) propofol 1.0mg/kg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2) propofol 0.5mg/kg group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3) normal saline group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>According to randomly allocated group, propofol 1.0mg/kg, propofol 0.5mg/kg or normal saline will be intravenously administered at the end of surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of propofol 1.0mg/kg</intervention_name>
    <arm_group_label>1) propofol 1.0mg/kg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol 0.5mg/kg</intervention_name>
    <arm_group_label>2) propofol 0.5mg/kg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <arm_group_label>3) normal saline group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. children (2-12 years old) scheduled for elective strabismus surgery undergoing
             general anesthesia.

          2. ASA 1-2

        Exclusion Criteria:

        1. Patients with developmental disability, mental retardation, neurologic disorder,
        ongoing neurologic medication such as anticonvulsant, previously undergoing general
        anesthesia, a recent history of upper respiratory infection, parents difficult to read or
        understand the informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Min-Soo KIM, MD</last_name>
    <phone>02-2019-3522</phone>
    <email>kmsviola@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gangnam Severance Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min-Soo KIM, MD</last_name>
      <phone>02-2019-3522</phone>
      <email>kmsviola@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>May 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>emergence agitation</keyword>
  <keyword>propofol</keyword>
  <keyword>strabismus surgery</keyword>
  <keyword>children</keyword>
  <keyword>elective strabismus surgery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Strabismus</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
